vTv Therapeutics Inc. (NASDAQ:VTVT) Given Average Recommendation of “Moderate Buy” by Brokerages

vTv Therapeutics Inc. (NASDAQ:VTVT) has received an average rating of “Moderate Buy” from the seven brokerages that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $53.00.

Several equities analysts have recently issued reports on VTVT shares. Zacks Research raised shares of vTv Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, May 13th. BTIG Research reaffirmed a “buy” rating and issued a $49.00 price objective on shares of vTv Therapeutics in a research note on Wednesday, March 11th. Weiss Ratings raised shares of vTv Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a research note on Monday, May 18th. Evercore started coverage on shares of vTv Therapeutics in a research note on Thursday, March 12th. They issued an “outperform” rating and a $44.00 price objective on the stock. Finally, Wall Street Zen raised shares of vTv Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th.

vTv Therapeutics Stock Down 0.2%

Shares of NASDAQ:VTVT opened at $32.94 on Thursday. The company has a market cap of $129.78 million, a PE ratio of -35.42 and a beta of 0.27. The company’s 50-day moving average price is $35.56 and its 200 day moving average price is $35.00. vTv Therapeutics has a fifty-two week low of $14.00 and a fifty-two week high of $44.00.

vTv Therapeutics (NASDAQ:VTVT) last released its earnings results on Wednesday, May 13th. The biotechnology company reported $1.65 EPS for the quarter, beating the consensus estimate of $0.21 by $1.44. The company had revenue of $36.84 million for the quarter, compared to analyst estimates of $20.00 million. As a group, equities analysts anticipate that vTv Therapeutics will post -2.19 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in VTVT. Baker BROS. Advisors LP boosted its holdings in shares of vTv Therapeutics by 52.4% during the third quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock worth $3,463,000 after purchasing an additional 51,000 shares during the period. Geode Capital Management LLC boosted its holdings in shares of vTv Therapeutics by 84.3% during the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after purchasing an additional 12,896 shares during the period. Goldman Sachs Group Inc. acquired a new stake in shares of vTv Therapeutics during the fourth quarter worth approximately $221,000. Finally, 683 Capital Management LLC acquired a new stake in shares of vTv Therapeutics during the fourth quarter worth approximately $731,000. 17.51% of the stock is owned by hedge funds and other institutional investors.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.